Malachite Innovations, Inc. (MLCT)

OTCMKTS: MLCT · Delayed Price · USD
0.170
0.00 (0.00%)
Oct 4, 2022 1:00 PM EDT - Market open
0.00%
Market Cap 8.75M
Revenue (ttm) n/a
Net Income (ttm) -1.93M
Shares Out 51.45M
EPS (ttm) -0.02
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 700
Open 0.160
Previous Close 0.170
Day's Range 0.160 - 0.170
52-Week Range 0.120 - 0.500
Beta 3.08
Analysts n/a
Price Target n/a
Earnings Date n/a

About MLCT

Malachite Innovations, Inc., together with its subsidiaries, provides health and wellness products in the United States. It offers a portfolio of approximately 100 novel cannabosides, including glycosylated tetrahydrocannabinol, cannabidiol, cannabidivarin, and cannabinol. The company also develops THC-glycoside (VBX-100), an oral prodrug for the treatment of gastrointestinal diseases, including inflammatory bowel disease and irritable bowel syndrome. In addition, it engages in identifying, investing in, and repositioning environmental situatio... [Read more...]

Industry Biotechnology
Founded 2007
Employees 3
Stock Exchange OTCMKTS
Ticker Symbol MLCT
Full Company Profile

News

MALACHITE INNOVATIONS ANNOUNCES CLOSING OF $3.0 MILLION CAPITAL RAISE AND INITIAL ESG ACQUISITIONS

CLEVELAND, OHIO, May 13, 2022 (GLOBE NEWSWIRE) -- MALACHITE INNOVATIONS, INC. (OTC Mkts: MLCT) (“Malachite”) announces the closing of a $3.0 million capital raise and purchase of 80% of the common stock...

4 months ago - GlobeNewsWire

MALACHITE INNOVATIONS ANNOUNCES SIGNED LETTER OF INTENT WITH RANGE ENVIRONMENTAL RESOURCES, INC.

CLEVELAND, OHIO, March 15, 2022 (GLOBE NEWSWIRE) -- MALACHITE INNOVATIONS, INC. (OTC Mkts: MLCT) (“Malachite”) announces that it has entered into a non-binding letter of intent (the “Letter of Intent”) ...

6 months ago - GlobeNewsWire

MALACHITE INNOVATIONS ANNOUNCES TWO GRANTED U.S. PATENTS AND NEW PCT PATENT FILING

CLEVELAND, OHIO, Dec. 28, 2021 (GLOBE NEWSWIRE) -- MALACHITE INNOVATIONS, INC. (OTC Mkts: MLCT) announces that its wholly-owned drug development subsidiary, Graphium Biosciences, Inc., has been granted ...

9 months ago - GlobeNewsWire

Vitality Biopharma Announces Effective S-1 Registration Statement and DTC Eligibility

CLEVELAND, Sept. 02, 2021 (GLOBE NEWSWIRE) -- Vitality Biopharma, Inc. (OTC Mkts: VBIO) (“Vitality” or the “Company”), an innovation-driven drug development company dedicated to unlocking the therapeuti...

1 year ago - GlobeNewsWire